GlobalData, a research and consulting firm, reported that the global Rheumatoid Arthritis (RA) treatment market value will witness steady growth, from $15.6 billion in 2013 to $19.3 billion in 2023.
GlobalData believes that the market expansion for RA treatment over the coming decade will be driven by increased RA prevalence, as well as the anticipated launches of novel drugs.
The products include three interleukin-6 inhibitors, four biologics novel to the RA market, four Janus kinase (JAK) inhibitors, and numerous biosimilars.
Heather Leach, Ph.D., GlobalData's Analyst covering Immunology, said, "Drugs with novel mechanisms of action, including biologics and small molecules, are welcome additions to the RA therapeutics market. However, this arena will become increasingly crowded over the next decade."
RA is an attractive therapy area for pharmaceutical companies as it is dominated by expensive biologics, and oral JAK inhibitors entering the market are expected to be priced only at a slight discount.
Perhaps the most anticipated event in the RA space is the addition of biosimilars, which are assumed to be priced at a 30% discount to the reference product.
Leach added that while the launch of biosimilars will provide a less expensive therapy option for patients, their lack of regulatory guidelines would delay their availability in a number of regions.
The company's latest report states that US boasts the largest RA treatment space, with a 67% share in 2013 among the 10 major pharmaceutical markets (the US, France, Germany, Italy, Spain, the UK, Japan, Australia, China, and India).